Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Rune Nielsen; Hannu Kankaanranta; Leif Bjermer; Peter Lange; Sofie Arnetorp; Morten Hedegaard; Anna Stenling; Nicole Mittmann

doi:10.1016/j.rmed.2013.06.007

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Rune Nielsen, Hannu Kankaanranta, Leif Bjermer, Peter Lange, Sofie Arnetorp, Morten Hedegaard, Anna Stenling, Nicole Mittmann

Section of Social Medicine

Research output: Contribution to journal › Journal article › Research › peer-review

7 Citations (Scopus)

Abstract

Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).

Original language	English
Journal	Respiratory Medicine
Volume	107
Issue number	11
Pages (from-to)	1709-21
Number of pages	13
ISSN	0954-6111
DOIs	https://doi.org/10.1016/j.rmed.2013.06.007
Publication status	Published - Nov 2013

Access to Document

10.1016/j.rmed.2013.06.007

Cite this

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. / Nielsen, Rune; Kankaanranta, Hannu; Bjermer, Leif; Lange, Peter; Arnetorp, Sofie; Hedegaard, Morten; Stenling, Anna; Mittmann, Nicole.

In: Respiratory Medicine, Vol. 107, No. 11, 11.2013, p. 1709-21.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{fb3f315b2118469ea8871b3d0567b758,

title = "Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries",

abstract = "Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler({\textregistered})+tiotropium (TIO) HandiHaler({\textregistered}) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).",

author = "Rune Nielsen and Hannu Kankaanranta and Leif Bjermer and Peter Lange and Sofie Arnetorp and Morten Hedegaard and Anna Stenling and Nicole Mittmann",

year = "2013",

month = nov,

doi = "10.1016/j.rmed.2013.06.007",

language = "English",

volume = "107",

pages = "1709--21",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

AU - Nielsen, Rune

AU - Kankaanranta, Hannu

AU - Bjermer, Leif

AU - Lange, Peter

AU - Arnetorp, Sofie

AU - Hedegaard, Morten

AU - Stenling, Anna

AU - Mittmann, Nicole

PY - 2013/11

Y1 - 2013/11

N2 - Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).

AB - Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).

U2 - 10.1016/j.rmed.2013.06.007

DO - 10.1016/j.rmed.2013.06.007

M3 - Journal article

C2 - 23856511

VL - 107

SP - 1709

EP - 1721

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 11

ER -